Episodic Migraine. Migraine
Conditions
Interventions
Intervention 1: Intervention group: Thiamin (300 mg), dana darou company, three times daily for 12 weeks. Intervention 2: Control group: Placebo (300 mg), dana darou company, three times daily for 12
Sponsors
Shahid Beheshti University of Medical Sciences, Nutrition and Food Industries Research Institute
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Willingness to participate in the study 18 to 45 years old BMI between 18.5-30 Diagnosis of episodic migraine headache based on the criteria of the Classification Committee of the International Headache Society (IHS) 3rd edition (beta version) Suffering from headache for more than three months Not taking a new medication to prevent migraine headache or changing its dose in the last 2 months
Exclusion criteria
Exclusion criteria: Vitamin B1 supplement consumption with any dose and consumption of any type of multivitamin containing vitamin B1 during the last three months Pregnancy and lactation Use of antipsychotic drugs Smoking Having known gastrointestinal diseases (malabsorption, IBD, etc.), diabetes, liver disorders (cirrhosis and types of hepatitis), kidney disorders (renal failure), congestive heart failure, high blood pressure, cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of headache attacks per month. Timepoint: Baseline and at the end of the study. Method of measurement: Daily headache registration questionnaire.;Severity of headache attacks. Timepoint: Baseline and at the end of the study. Method of measurement: Daily headache registration questionnaire - visual analog scale.;Duration of headache attacks. Timepoint: Baseline and at the end of the study. Method of measurement: Daily headache registration questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number and dose of painkillers. Timepoint: Baseline and at the end of the study. Method of measurement: Daily headache registration questionnaire.;Serum Calcitonin gene-related peptide (CGRP) level. Timepoint: Baseline and at the end of the study. Method of measurement: Blood test.;The activity level of Erythrocyte transketolase enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Blood test.;Serum vitamin B1 level. Timepoint: Baseline and at the end of the study. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSoodeh Razeghi Jahromi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed